Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Up 106.2% in April

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 40,413 shares, an increase of 106.2% from the April 15th total of 19,602 shares. Approximately 1.1% of the shares of the company are sold short. Based on an average trading volume of 43,030 shares, the days-to-cover ratio is currently 0.9 days.

Pulmatrix Stock Down 1.6%

Shares of Pulmatrix stock traded down $0.02 during trading on Friday, reaching $1.25. The company’s stock had a trading volume of 17,492 shares, compared to its average volume of 31,072. The business’s 50-day moving average price is $1.56 and its 200-day moving average price is $2.73. The firm has a market cap of $4.56 million, a PE ratio of -0.89 and a beta of 1.94. Pulmatrix has a 52 week low of $1.16 and a 52 week high of $9.37.

Pulmatrix (NASDAQ:PULM) last announced its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).